Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is…
Sector
Healthcare
Exchange
NASDAQ
Country
US
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Climb Bio (CLYM) Analysis Tools & Insights
Income Statement